Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Abata Therapeutics
Abata Therapeutics develops cell therapy to treat autoimmune and inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Quell Therapeutics
Quell aims to be a leading Treg cell therapy company.
Sector
Subsector
Keywords
Location
total rounds
total raised
Rubius Therapeutics
Rubius Therapeutics develops Red-Cell Therapeutics to treat rare diseases, cancer, and autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
Cell Care Therapeutics
The company Cell Care Therapeutics is developing regenerative immunotherapies derived from the secretions of adult stem cells.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds5
Number of Funding Rounds
Money Raised
Their latest funding was raised on 04.09.2024. Their latest investor Regeneron. Their latest round Corporate Round
Regeneron
Regeneron Pharmaceuticals invents life-transforming medicines for people with serious diseases..
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Regeneron
Regeneron Pharmaceuticals invents life-transforming medicines for people with serious diseases..
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Ally Bridge Group
Ally Bridge Group is a global healthcare-focused investment group.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors19
Number of lead investors
Number of investors
Regeneron
Regeneron Pharmaceuticals invents life-transforming medicines for people with serious diseases..
Sector
Subsector
Location
total rounds
total raised
count Of Investments
Milky Way Ventures
Milky Way Ventures is an eCommerce incubator creating marketplace startups in Italy.
Sector
Subsector
Keywords
Location
count Of Investments
Octagon Capital Partners
Octagon Capital Partners is a venture capital firm that primarily invests in startups in the Supply Chain Management and Hardware sectors.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders4
Fred Ramsdell
Fred Ramsdell, Ph.D., is a veteran biotechnology leader in immunology with nearly three decades of experience. Fred is a founder of Sonoma and serves at the Chief Scientific Officer. Immediately prior to Sonoma, Fred was the CSO at the Parker Institute for Cancer Immunotherapy (PICI) where he helped to build and advance multiple research programs from the inception of the Institute. After a fellowship at the NIH, Fred joined Immunex studying T cell activation and tolerance, with a focus on gene discovery and functional characterization. He later joined Darwin Molecular (which was later acquired by Celltech R&D) to establish the immunology program. Amongst other programs, he led the team that discovered and characterized FoxP3, a gene critical to the function of regulatory T-cells. Fred joined ZymoGenetics in 2004, where he led teams studying novel proteins with potential regulatory activity in lymphoid cells. In 2008, Novo Nordisk brought Dr. Ramsdell on to help establish the company’s new Inflammation Research Center in Seattle and lead the Immunobiology group. He earned his doctoral degree in microbiology and immunology from the University of California, Los Angeles and holds a bachelor’s degree in biochemistry and cell biology from the University of California, San Diego.
current job
organization founded
Fred Ramsdell
Qizhi Tang
Dr. Tang received her bachelor's degree at Peking Union Medical College in China. She completed her graduate education in the US, getting her master's degree from the University of South Alabama and her PhD from the University of Illinois at Chicago. She completed post doctoral fellowships at the University of Illinois at Chicago and under renowned immunologist Dr. Jeffrey Bluestone at the University of Chicago and the University of California, San Francisco. Dr. Tang joined the staff at the University of California, San Francisco in 2002 as an Assistant Professor of Pathology in the Diabetes Center where she focused on immune tolerance. She joined the transplantation department in 2007 to lead basic research on transplant immunology. She now focuses on regulatory T cell biology. She is one of the first to grow regulatory T cells and apply these cells in experimental therapy. In addition to Dr. Tang's research duties, she has presented several national lectures. She has also published dozens of articles in the field of immunology. Qizhi Tang Scientific Advisor
current job
organization founded
Qizhi Tang
Jeffrey Bluestone
Jeffrey Bluestone, PhD is CEO and President, Parker Institute for Cancer Immunotherapy and the A.W. and Mary Margaret Clausen Distinguished Professor at UCSF. A leading researcher in immune tolerance and T-cell activation, he has developed multiple immunotherapies including the first FDA-approved drug targeting T-cell co-stimulation in autoimmune disease and organ transplantation, and CTLA-4 antagonist drugs approved to treat metastatic melanoma. As an academic leader on a national and international scale he was founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy. As former UCSF Executive Vice Chancellor and Provost, and former Director of the UCSF Diabetes Center, he has authored over 400 peer-reviewed publications and received numerous awards including election to the American Academy of Arts and Sciences, the National Academy of Medicine and as member of Vice President Biden’s Cancer Moonshot Blue Ribbon Panel.
current job
organization founded
Jeffrey Bluestone
Alexander Rudensky
Alexander Rudensky, PhD, an immunologist at Memorial Sloan Kettering Cancer Center, is co-discoverer of the transcription factor FoxP3 that is essential for Treg identification and function. Early in his career, Dr. Rudensky pursued biochemistry at Moscow’s Second Medical School, studying the interplay between the immune system’s main actors: T cells and B cells. Following postdoctoral work at Yale, he accepted a professorship at the University of Washington, where his focus turned to the molecular underpinnings of T cell development. Rudensky became particularly interested in regulatory T cells, or Tregs, thought to play a role in suppressing unwanted immune responses. The molecular identity and role of Tregs had puzzled researchers for decades, but Rudensky and his team helped solve it by discovering that the gene switch FOXP3 controls their formation. Much of Rudensky’s career unfolded at Memorial Sloan-Kettering in New York City. Notably, he found that placental mammals form cohort of “peripheral” Tregs, and that during pregnancy, these Tregs prevent the maternal immune system from attacking the fetus, effectively linking peripheral Treg deficiency to miscarriages. Rudensky also discovered that fatty acids in the gut boost the formation of peripheral Tregs, which in turn help ward off inflammatory gut disorders, and that Tregs secrete a signaling molecule that mediates tissue repair and maintenance, establishing a central role for them in inflammation and allergies. More recently, Rudensky and his colleagues have explored how Tregs influence cancer progression. Clinical trials involving Tregs in transplantation and autoimmune diseases are underway, and the coming years are poised to bring promising leads for cancer treatment.
current job
organization founded
Alexander Rudensky
Employee Profiles11
Sejal Hall
Vice President, Program, Portfolio & Alliance Management
Fred Ramsdell
Co-Founder & Chief Scientific Officer
Activity
Recent News5
The graph reveals the ratio (%) of positive news articles in a chosen time range